Inotrem Raises €18 million to Develop Innovative Sepsis Treatments in a Series A Financing Co-led by Edmond de Rothschild Investment Partners and Sofinnova Partners

Paris and Nancy, France, March 13 2014 – Inotrem S.A., a French biotech company specialized in the control of immune reaction in acute inflammatory diseases, announced today the completion of its Series A financing round. With a total of €18 million, this round is the largest Series A round in Europe this year. The round was co-led by leading international life science venture capitalists Edmond de Rothschild Investment Partners and Sofinnova Partners. Switzerland-based Biomed Invest and the French seed investment firm Inserm Transfert Initiative also participated in the round. Gilles Nobécourt of Edmond de Rothschild Investment Partners and Graziano Seghezzi of Sofinnova Partners have joined the Supervisory Board of Inotrem.

Based on the pioneering research work of Prof. Sebastien Gibot, professor of Critical Care Medicine at the University of Lorraine Medical School in Nancy; and Dr. Marc Derive, co-founder and CSO of Inotrem, the company has built a strong expertise around TREM-1, a pathway functioning as an amplifier of the immune response cycle. TREM-1 is particularly up-regulated in patients suffering from sepsis, an acute and severe infectious and inflammatory syndrome which can lead to multiple organ failure and death. Sepsis has an increasing incidence worldwide, affecting up to 1% of the population annually with a mortality rate of 50%, placing sepsis as the 10th leading cause of death in developed countries. There are currently no specific mechanistically targeted therapies approved for this indication besides antibiotics and symptomatic agents.

Inotrem is developing an inhibitor of TREM-1 that has shown promising activity in a very broad series of sepsis animal models. The company is also working on a biomarker strategy to deliver a personalized healthcare solution with the aim to identify patients who would most likely benefit from the treatment.

This Series A round will support development of Inotrem's lead product through late stage preclinical and early clinical trials in sepsis, plus the characterization of its therapeutic potential in other inflammatory diseases. 

Dr Jean-Jaques Garaud, CEO of Inotrem and formerly Head of Research and Early Development at Roche, commented: "Our primary objective is to deliver to the medical community novel treatments to help fight the dire consequences of severe infections. Inotrem is developing one of the most promising approaches to tackle such a devastating condition. We are very proud and blessed to have now been recognized with the support of such a strong investor syndicate."